1. Home
  2. ESLT vs UTHR Comparison

ESLT vs UTHR Comparison

Compare ESLT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elbit Systems Ltd.

ESLT

Elbit Systems Ltd.

HOLD

Current Price

$819.48

Market Cap

31.4B

Sector

Industrials

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$500.51

Market Cap

20.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESLT
UTHR
Founded
1966
1996
Country
Israel
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.4B
20.4B
IPO Year
2002
1999

Fundamental Metrics

Financial Performance
Metric
ESLT
UTHR
Price
$819.48
$500.51
Analyst Decision
Buy
Buy
Analyst Count
3
13
Target Price
$550.33
$520.00
AVG Volume (30 Days)
128.0K
336.2K
Earning Date
01-01-0001
05-28-2026
Dividend Yield
0.33%
N/A
EPS Growth
N/A
13.07
EPS
N/A
27.86
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$17.91
$8.56
Revenue Next Year
$9.55
$10.71
P/E Ratio
$71.88
$18.48
Revenue Growth
N/A
2.38
52 Week Low
$343.00
$266.98
52 Week High
$833.25
$537.19

Technical Indicators

Market Signals
Indicator
ESLT
UTHR
Relative Strength Index (RSI) 75.25 54.45
Support Level $436.67 $463.64
Resistance Level N/A $516.36
Average True Range (ATR) 25.41 18.43
MACD 9.88 3.39
Stochastic Oscillator 93.17 47.44

Price Performance

Historical Comparison
ESLT
UTHR

About ESLT Elbit Systems Ltd.

Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: